Brilinta No Better Than Plavix for PAD

ACC Conference Reporter

AHA 2016 | NEW ORLEANS — Ticagrelor (Brilinta) and clopidogrel (Plavix) were neck and neck in terms of efficacy and safety for treating peripheral artery disease (PAD), according to results of the late-breaking EUCLID trial presented here. Read More >>>

Keywords: AHA Annual Scientific Sessions, AHA16

< Back to Listings